Podcasts about Heart failure

This month on Episode 73 of Discover CircRes, host Cindy St. Hilaire highlights articles featured in the May 23rd and June 6th issues of Circulation Research. This Episode also includes a discussion with Dr Jae Min Cho and Tzung Hsiai, about their study, Habitual Exercise Modulates Neuroimmune Interaction to Mitigate Aortic Stiffness.   Article highlights: Interorgan Crosstalk in Heart Failure and Cardiometabolic Diseases: A Compendium He, et al. NEP in Placental EVs Triggers Hypertension in PE Dennis, et al. FoxO1-zDHHC4-CD36 S-Acylation Axis in Diabetes

On this episode of JHLT: The Podcast, the Digital Media Editors invite first author Nikil Prasad, MD, a cardiology fellow in the Columbia University Medical Center in New York, to discuss the paper, “Can the grading of mild cardiac allograft vasculopathy be further refined? An angiographic and physiologic assessment of heart transplant recipients with ISHLT CAV 1.” The discussion explores: The study's subdivisions of CAV grade 1 into CAV 1a and CAV 1b, based on the degree of coronary stenosis Differing clinical information provided by different methods of CAV screening: reduced myocardial blood flow reserve vs angiographic grading Limitations in implementing PET-based CAV assessments at various centers, and how transplant programs can use combined testing data For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt. Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

In this podcast, Ty J. Gluckman, MD, MHA, discusses the pivotal phase III FINEARTS-HF trial and how the treatment landscape is evolving for patients with heart failure (HF) with mildly reduced or preserved ejection fraction, including:The emerging role of mineralocorticoid receptor antagonists in HF careFinerenone's efficacy in reducing composite cardiovascular death and worsening HF events Why safety must be monitored, especially considering hyperkalemia riskWhere HF guideline recommendations lack compared with the current evidence PresenterTy J. Gluckman, MD, MHAMedical Director, Center for Cardiovascular Analytics, Research, and Data Science (CARDS)Providence Heart InstituteProvidence Health SystemPortland, OregonProgram page: https://bit.ly/448XcH0

Each year, more than 800,000 Americans suffer a heart attack and many of those who survive are left with irreversible scarring and the slow progression towards heart failure. In this episode, Edward Thorp, PhD, explains how his team is exploring immune cells that influence the heart's ability to heal after such injuries. In Thorp's lab, they are uncovering fundamental molecular mechanisms by which the immune system regulates wound repair, reduces inflammation and regenerates tissue. 

Welcome back to this week's Friday Review where I can't wait to share with you the best of the week!     I'm looking forward to reviewing:     Magic Molecule (product review) Four Thousand Weeks (book review) Autoimmune Disease & Heart Failure (research) Collagen & Joint Support (research)     For all the details tune into this week's Cabral Concept 3416 – Enjoy the show and let me know what you thought!   - - - For Everything Mentioned In Today's Show: StephenCabral.com/3416 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

In this episode, host Mitsuaki Sawano, MD, is joined by Dr. Shoichiro Yatsu, MD, to discuss his sub-analysis of the ADVENT-HF trial, recently published in JACC: Heart Failure. The study investigates the effects of peak-flow-triggered adaptive servo-ventilation (ASVPF) on left ventricular (LV) structure and function in patients with heart failure and sleep-disordered breathing (SDB). Compared to earlier studies using different ASV algorithms, ADVENT-HF highlights the safety and clinical value of ASVPF, showing meaningful improvements in sleep quality, symptoms, and quality of life. Dr. Yatsu also shares insights from managing legacy trial data collected over more than a decade.

This week is Heart Rhythm Awareness Week, a national campaign focusing on educating the public about heart rhythm disorders, particularly atrial fibrillation. In Ireland, one in four deaths are caused by heart disease and stroke each year For more Prof. Mark Dayer, Head of Heart Failure and Consultant Cardiologist at the Mater Private in Dublin.

With Kevin Damman, University Medical Center Groningen, Groningen - The Netherlands, Floran Sahiti, University Hospital of Wurzburg, Wurzburg - Germany, Joao Pedro Ferreira, University of Porto, Porto - Portugal, Novi Yanti Sari, Siloam Hospitals Group, Jakarta - Indonesia, Marat Fudim, Duke University Medical Center, Durham, NC - USA, Gregorio Tersalvi, Mayo Clinic, Rochester, MN - USA, Jose Luis Morales Rull, University Hospital Arnau de Vilanova, Lleida - Spain and Cornelia Margineanu, Bucharest - Romania. In this episode, we discuss four late-breaking clinical trials presented at the Heart Failure Congress 2025 in Belgrade, Serbia. First, Kevin Damman presents the results of FUTURE-HF, a first-in-human study evaluating the long-term safety, accuracy, and clinical utility of a novel implantable IVC sensor for remote heart failure management. Next, Joao Pedro Ferreira highlights the key findings of SOGALDI-PEF, a crossover trial comparing SGLT2 inhibitor monotherapy versus combination therapy with an SGLT2 inhibitor and a mineralocorticoid receptor antagonist (MRA) in reducing NT-proBNP levels. Third, Marat Fudim reports on the MUSIC-HFpEF phase 1/2a trial, which explores the safety and preliminary efficacy of a novel gene therapy using adeno-associated virus vectors in patients with HFpEF. Finally, Jose Luis Morales Rull shares insights from PREFER-HF, a study assessing the effects of intravenous or oral iron therapy versus placebo in patients with HFpEF and iron deficiency anemia. FUTURE-HF: Long-term safety, accuracy, and utility of a novel implantable IVC sensor for remote HF management - Kevin Damman, University Medical Center Groningen, Groningen, The Netherlands. Host: Floran Sahiti, University Hospital of Wurzburg, Wurzburg, Germany doi: 10.1016/j.jchf.2025.01.019. SOGALDI-PEF: SOdium-Glucose cotransporter 2 inhibitor with and without an ALDosterone AntagonIst for heart failure with preserved ejection fraction – Joao Pedro Ferreira, University of Porto, Porto, Portugal. Host: Novi Yanti Sari, Siloam Hospitals Group, Jakarta (Indonesia).  MUSIC-HFpEF: Gene therapy in Heart Failure with Preserved Ejection Fraction – Marat Fudim, Duke University Medical Center, Durham, NC, USA. Host: Gregorio Tersalvi, Mayo Clinic, Rochester, MN, USA PREFER¬-HF: Effects intravenous iron or oral iron therapy compared to placebo in HFpEF with iron deficiency anemia - Jose Luis Morales Rull, University Hospital Arnau de Vilanova, Lleida, Spain. Host: Cornelia Margineanu, Bucharest, Romania. This 2025 HFA Cardio Talk podcast series is supported by Bayer AG in the form of an unrestricted financial support. The discussion has not been influenced in any way by its sponsor.

In this episode, Dr. Valentin Fuster discusses groundbreaking research validating the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) as a powerful real-world predictor of heart failure outcomes using advanced machine learning on outpatient data. Emphasizing the critical importance of patient-reported health status, he highlights that listening to patients remains essential even in an era dominated by AI-driven medicine.

This episode and sources present a snapshot of AI developments on June 06th, 2025, highlighting several key areas. Google and Anthropic announced significant model updates, with Google enhancing its general Gemini model and Anthropic introducing a specialised version for the US government. AI is also being applied in diverse fields, including a new scanner for predicting heart failure and its use in archaeology and radiology for improved analysis. Concerns around AI misuse are addressed by OpenAI identifying and disrupting propaganda campaigns utilising AI tools. Furthermore, the integration of AI in daily life is seen through Walmart's expansion of drone delivery and Google's testing of a real-time search feature. Finally, the competitive nature of the AI landscape is evident, as Anthropic stated it would not sell its AI models to OpenAI.

In this piece we discuss the intricacies of right heart failure, the differences between the right and left ventricles, and the challenges of early detection and monitoring. With a focus upon research we discuss the Swan-Ganz IQ pulmonary artery catheter, with the FastCCO algorithm, from BD Advanced Patient Monitoring. We cover its innovative capabilities, explore its impact on patient care and look particularly at high-risk patients like those with pulmonary hypertension and LVADs. The episode highlights the importance of new monitoring techniques, future research directions, and the promise of continuous data in improving right ventricular function diagnosis and treatment. Presented by Kate Leslie with her guest Joerg Ender, Director of the Department for Anesthesiology and Intensive Care Medicine, Heart Center, Leipzig, Germany. He is second president of the German Society of Anesthesiology and Intensive Care Medicine and former Secretary General of the European Association of Cardiothoracic Anaesthesiologists (EACTA).

For full review of the trials, please visit https://cardiologytrials.substack.com/ Get full access to Cardiology Trial's Substack at cardiologytrials.substack.com/subscribe

Some music and sounds in this podcast by @itslucakoala In this BRAND NEW podcast episode — Brittany invites on to chat with her, Kate Safris. She is one of the original founders of ‘Healthy Birthday INC'. She proudly brings awareness to expecting families about the importance of monitoring fetal movement. In this 4 part May podcast series Kate and Brittany deep dive into all things involving child loss, rainbow babies,  the importance of tracking fetal movement….and more. Brittany and Kate will discuss in full detail the @countthekicksus app and how it can help possibly prevent fetal demise. Please learn more about ‘COUNT THE KICKS' and you can download the FREE app today to track your babies movement while in utero.  Please enjoy episodes 1, 2, and 3 are out now! Episode 4 to drop soon. Discussed in this episode — Why wasn't Emma's heart failure caught sooner? : Kate explains — The shock of Kate and husband learning about their daughters' fate — Overcoming grief & loss as a family — Kate begins to discuss her involvement with ‘Count the Kicks' — Kate begins to discuss research and much more regarding monitoring fetal movement while in utero — And much more! AG1: NEXT GEN JUST LAUNCHED! So subscribe today to try the Next Gen of AG1! If you use my link, you'll also get a FREE bottle of AG D3K2, an AG1 Welcome Kit, AND 5 of the upgraded AG1 travel packs with your first order. So make sure to check out DrinkAG1.com/bosbabes to get started with AG1's Next Gen and notice the benefits for yourself.   Get 15% OFF of your FULL Manscaped order by going to manscaped.com and using my code BRITTANY at checkout For all of your furniture needs please be sure to check out Highpoint Furniture Sales. They are fully family owned and operated with 1 great location in the state of North Carolina— visit their showroom In High Point or shop their website highpointfurnituresales.com — they offer white glove delivery and set up services nationwide! For your triad area realty needs please get in touch with Amy Cromer of ‘Cromer Property Group'. Visit her website today for more information www.cromerpropertygroup.com Luca Koala FREE music on Spotify: https://open.spotify.com/album/5kepJgtnHDGsvYiLlKXQ03?si=wZKjnpjvTXSXz-qnBOkX7w

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Prognostic Value of Pericoronary Fat Attenuation Index on Computed Tomography for Hospitalization for Heart Failure.

Role of Genetics in the Heart Failure Clinic   Guest: Naveen Pereira, M.D. Host: Kyle Klarich, M.D.   Genetic testing for heart failure is most beneficial for patients with cardiomyopathies. It aids in personalized treatment, early diagnosis, and family risk assessment, although its uptake has been slow due to costs, access, and interpretation challenges. Ongoing research into genetic mutations and their role in cardiomyopathy pathophysiology could lead to new therapeutic targets and improved disease management.   Topics Discussed: Which patients with heart failure should get genetic testing? Why should genetic testing be performed? How is genetic testing performed? Why has there been a slow uptake in genetic testing for patients with cardiomyopathy?  And what are some possible solutions? Can genetics provide new insight into the pathophysiology of disease, specifically cardiomyopathies? Can this information then be used to help developed new therapeutic targets? What are some of the uncertainties in the field that research should be focused on?   Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices. LinkedIn: Mayo Clinic Cardiovascular Services Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode. Podcast episode transcript found here.  

Story at-a-glance New data from the largest clinical trial on this topic shows no improvement in symptoms, hospitalizations, or survival with fluid restriction in chronic heart failure patients Patients who drank more than the advised limit of 1,500 ml had no higher risk of death, hospitalization, kidney injury, or emergency interventions Fluid-restricted patients reported much higher thirst distress, which contributes to stress hormone release, reduced treatment compliance, and increased emotional strain Over-restricting both water and salt leads to dangerously low sodium levels, while getting enough potassium helps your kidneys manage hydration and prevent harmful fluid buildup Researchers recommend giving fluid goals based on your symptoms, medications, and how you feel — this allows you more control and fewer restrictions

Is creatine safe? Does it just make you bloated? Is it only for bodybuilders? You've heard the rumors, now it's time to hear the truth from the world's leading expert on creatine.In this powerful episode of Sweat Success, we sit down with Dr. Richard Kreider, a pioneer in creatine research with over 1,000 published studies and decades of experience shaping sports science. He unpacks the real science behind creatine: its proven benefits for muscle growth, brain health, injury prevention, heart function, and even kids, seniors, and pregnant women.Whether you're a gym owner, high-performance athlete, health-conscious parent, or everyday lifter, this episode will shatter the myths and show you how creatine can radically support your health, performance, and recovery.

The BedMed trial of nighttime BP meds, SURMOUNT-5, Troponin URL, gene tests in patients with no disease, and guideline-directed medical therapy for HF are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Timing of BP Meds – The BedMed RCT MAPEC https://doi.org/10.3109/07420528.2010.510230 Hygia https://doi.org/10.1093/eurheartj/ehz754 Turgeon et al https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.121.16501 TIME trial https://doi.org/10.1016/S0140-6736(22)01786-X BedMed https://jamanetwork.com/journals/jama/fullarticle/2833860 Time Antihypertensives Taken Doesn't Matter: New Trials https://www.medscape.com/viewarticle/time-antihypertensives-taken-doesnt-matter-new-trials-2024a1000g3z Timing of BP Dosing Doesn't Matter: BedMed and BedMed-Frail https://www.medscape.com/viewarticle/timing-blood-pressure-dosing-doesnt-matter-again-bedmed-and-2024a1000fz2 Timing of Blood Pressure Meds Doesn't Affect Outcomes: BedMed in Print https://www.medscape.com/viewarticle/timing-blood-pressure-meds-doesnt-affect-outcomes-bedmed-2025a1000cdm II Tirzepatide vs Semaglutide SURMOUNT 5 https://www.nejm.org/doi/full/10.1056/NEJMoa2416394 III Age-specific Troponins Coyle and McEvoy https://doi.org/10.1093/eurheartj/ehaf308 Mandrola/Foy JAMA-IM https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2777967 IV Return to Play for Gene Positive Phenotype Negative athletes Martinez et al https://doi.org/10.1016/j.jacep.2025.03.013 V Rapid Titration of GDMT in HF STRONG HF: More Beats Less After Discharge for Heart Failure https://www.medscape.com/viewarticle/983698 JACC-HF Substudy https://doi.org/10.1016/j.jchf.2025.02.020 STRONG HF https://doi.org/10.1016/S0140-6736(22)02076-1 AVID https://www.nejm.org/doi/full/10.1056/NEJMoa013474 EAST https://www.nejm.org/doi/full/10.1056/NEJMoa013474 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

N Engl J Med 1996;334:1349-1355Background Before 1990, the prevailing idea held that the negative inotropy of beta-blockers would harm patients with impaired systolic function. Yet part of the progression of systolic heart failure involved over stimulation of the sympathetic nervous system. Norepinephrine can exert adverse effects on the circulation, both directly and indirectly. Smaller trials of beta-blockers in systolic heart failure found trends for benefit with beta-blockers, however, a mortality benefit had not yet been proven. The U.S. Carvedilol Heart Failure Study aimed to study mortality in patients with heart failure with a reduced ejection fraction.Cardiology Trial's Substack remains free of industry ads because of your support. Thank you. Please consider becoming a free or paid subscriber.Patients The study enrolled 1094 patients with chronic heart failure symptoms for at least 3 months, LVEF ≤ 0.35%, at least 2 months of treatment with diuretics and an angiotensin-converting enzyme (ACE) inhibitor (if tolerated). Treatment with digoxin, hydralazine, or nitrates was permitted but not required.Exclusion criteria were extensive and important to understand. These included any recent major cardiac events or surgery within the previous 3 months, uncorrected valvular disease, active myocarditis, sustained VT or higher degrees of AV block not controlled by pacing, systolic blood pressure of more than 160 or less than 85 mm Hg or diastolic blood pressure of more than 100 mm Hg, clinically significant kidney or liver disease or use of calcium-channel blockers, adrenergic agonists/antagonists, or class IC/III antiarrhythmic agents. Patients receiving β-adrenergic agonists or antagonists (presumably for another indication) were not enrolled.Baseline Characteristics The results of this and other beta-blocker trials in heart failure will be clear. One of the most important points for translating this evidence to patients will be the baseline characteristics. It is vital to understand who these patients were.The mean age was 58 years and approximately 76% were male. Most patients had mild to moderate heart failure, with 53% in NYHA Class II, 44% in Class III, and only 3% in Class IV. The etiology of heart failure was nearly evenly split between coronary artery disease (47%) and nonischemic cardiomyopathy (53%). Patients had significantly impaired cardiac function with a mean LVEF of 0.23. The mean six-minute walk distance ranged from 386 to 390 meters. Hemodynamic parameters were relatively stable, with mean systolic blood pressure of 116 mmHg, and mean heart rate of 83-84 beats per minute. Most patients were receiving standard heart failure therapy at baseline, including digitalis (90-91%), loop diuretics (95%), and ACE inhibitors (95%), while approximately one-third (32%) were on direct-acting vasodilators.Trial Procedures Patients were assessed for eligibility during a 3-week screening period during which exercise capacity was assessed with a 6-minute walk test. Notable was that these were outpatients able to complete a 6-minute walk test. Enrollment was stratified to one of four treatment protocols on the basis of the patients' performance on the exercise test: patients able to walk between 426 and 550 m when tested were assigned to the mild-heart-failure protocol; those able to walk between 150 and 425 m were assigned either to the moderate-heart-failure protocol or to a dose-ranging protocol, depending on the location of the study center; and those able to walk only less than 150 m were assigned to the severe-heart-failure protocol.After this base-line testing, all patients received 6.25mg of carvedilol twice daily for two weeks in an open-label run-in period. Those who tolerated this initial dose were then randomized to receive either placebo (n=398) or carvedilol (n=696) on a double-blind basis, in addition to their usual medications.The allocation ratio (carvedilol:placebo) was 2:1 in the mild and severe heart failure protocols and 1:1 in the moderate heart failure protocol. The dose was gradually increased to target levels of 25-50mg twice daily over 2-10 weeks, followed by maintenance therapy for an additional 6 months (12 months for mild heart failure).Endpoints At the time of trial planning, the original intent was safety. That is, to show that carvedilol did not increase mortality. The original intent was to enroll 1100 patients. As smaller trials on beta-blockers were published, the statistical plan included the possibility of beta-blocker benefit. The trialists therefore planned two sided statistical analysis.Cumulative survival curves were constructed as time-to-first-event plots by Kaplan–Meier survivorship methods and differences between the curves were tested for significance by the log-rank statistic with use of a Cox proportional-hazards regression model (which included the protocol as a covariate).Results Median follow-up was only 6.5 months due to early termination for benefit. The patients mean total daily dose of carvedilol was 45±27 mg. Overall mortality was 7.8% in the placebo group vs. 3.2% in carvedilol group. The relative risk reduction from carvedilol vs placebo was 65% (95% CI, 39-80%; p

Focus Issue on Heart Failure and Cardiomyopathies, Epidemiology, Prevention and Health Care Policies

We're taking a break this week, but we'll be back next week with a brand-new episode.  Provide superb outpatient care for your patients with HFrEF. Identify underlying causes of heart failure and titrate medications with ease. Dr Michelle Kittleson @MKittlesonMD (Cedars Sinai) breaks down the nuances of treating this common cardiac condition.  Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments 00:00 Introduction  03:22 Case Presentation: Newly Diagnosed Heart Failure 07:26 Using Physical Exam Findings to Guide Diuresis 11:58 The Four Pillars of Guideline-Directed Medical Therapy for Heart Failure 15:07 Optimizing Therapy and Follow-Up in Heart Failure Patients 22:10 The Benefits of High-Intensity Initiation and Titration of Guideline-Directed Medical Therapy 28:02 Consideration of Other Medications 40:02 Referral to Advanced Heart Failure Specialist 49:11 Optimizing Therapy and Follow-Up 55:33 Conclusion and Book Recommendation Credits Writer and Producer: Deborah Gorth MD, PhD Infographic and Cover Art: Zoya Surani Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Emi Okamoto MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Michelle Kittleson MD, PhD Sponsor: Mint Mobile  Get your summer savings and shop premium wireless plans at MINTMOBILE. com/CURB. Sponsor: American College of Physicians Order ACP MKSAP today at acponline.org. Curbsiders Listeners who use promo code  CORECS will receive a MKSAP gift pack with their subscription. Sponsor: Panacea Legal Learn more and schedule your free consultation at Panacea.Legal.

Diagnosed with end-stage heart failure, Sofia walks us through the mysterious early symptoms, her emergency hospitalization, and the rapid decision to receive an LVAD that now keeps her alive. You can follow Sofia on TikTok here.

We love to hear from our listeners. Send us a message.In this episode of Cell & Gene: The Podcast, Host Erin Harris sits down with Peter Altman, Ph.D., CEO of BioCardia, to discuss the company's evolution from a cardiac biotherapeutic delivery firm to a developer of autologous and allogeneic cell therapies for cardiovascular and pulmonary diseases. Altman highlights BioCardia's CardiAMP program, a precision medicine approach that pre-screens patients based on their cell profiles to improve trial outcomes and reduce costs. He explains why no cardiac cell therapy has yet received FDA approval, citing challenges in delivery, immune rejection, and arrhythmia risks. Altman outlines BioCardia's near-term roadmap, including regulatory submissions in the U.S. and Japan and the launch of a second trial focused on patients most likely to benefit.Subscribe to the podcast!Apple | Spotify | YouTube

On this episode of JHLT: The Podcast, the Digital Media Editors invite first author Peter Cho and senior author Abbas Ardehali, MD, to discuss the paper, “Severe primary graft dysfunction in heart transplant recipients using donor hearts after circulatory death: a United States Experience.” Peter is a third year medical student at Drexel University, and Dr. Ardehali is professor of surgery and medicine and the Director of the Heart, Lung, and Heart-Lung Transplant programs at UCLA. The episode explores: The study's findings regarding an increased incidence of severe PGD at 24 hours post-transplant in DCD over DBD recipients What risks weren't changed in DCD recipients—suggesting that DCD PGD is likely to be transient, and may have a different phenotype How NRP may impact the outcomes Mitigating the risk of PGD For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt. Tune in again later this month for the Digital Media Editors' findings and observations from the ISHLT2025 Annual Meeting in Boston. Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

Heart failure occurs when the heart muscle doesn't pump blood as well as it should and should not be confused with a heart attack. Leading and advanced treatment can help improve the symptoms of heart failure and may help some people live longer. Dr. Yoon will explain how MemorialCare Heart & Vascular Institute at Long Beach Medical Center helps those with heart failure live longer, while preserving their quality of life.

Acorai is pioneering non-invasive cardiac monitoring technology that combines multiple sensors and machine learning to transform heart failure management, making critical pressure measurements accessible and continuous.

In this three-part series, Jonathan Sackier speaks with Peder Langeland Myhre about cutting-edge advancements in heart failure research, the importance of biomarker-driven care, the challenges of implementing digital health tools globally, and how Norway is reshaping participation in cardiology clinical trials. Timestamps:  02:06 – Skiing & heart  04:02 – Blix award impact  07:51 – Heart failure biomarkers 

In this three-part series, Jonathan Sackier speaks with Peder Langeland Myhre about cutting-edge advancements in heart failure research, the importance of biomarker-driven care, the challenges of implementing digital health tools globally, and how Norway is reshaping participation in cardiology clinical trials. Timestamps:    00:21 – Biomarker disparities  04:52 – Norway trial challenges  07:15 – Boosting trial engagement 

In this three-part series, Jonathan Sackier speaks with Peder Langeland Myhre about cutting-edge advancements in heart failure research, the importance of biomarker-driven care, the challenges of implementing digital health tools globally, and how Norway is reshaping participation in cardiology clinical trials.  Timestamps:    00:17 – Digital health equity  06:00 – Podcasts in medicine  07:59 – Three cardiology wishes 

In this podcast, Dr. Valentin Fuster discusses a study published in the JACC examining the impact of obesity, insulin resistance, and diabetes on patients with heart failure and preserved ejection fraction. The findings suggest that while obesity is closely linked to heart abnormalities, insulin resistance and diabetes have a less direct impact, urging further research into cardiometabolic therapies and the role of body fat in managing heart failure.

In this podcast, Dr. Valentin Fuster explores a study on the effects of SGLT2 inhibitors, like empagliflozin, on erythropoiesis and iron mobilization in heart failure patients. The research reveals how these drugs activate key metabolic pathways, potentially enhancing iron utilization and improving clinical outcomes, with significant implications for treatment in heart failure and chronic kidney disease.

In this podcast, Dr. Valentin Fuster reviews findings from the SUMMIT trial, which examined how tirzepatide impacts patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and chronic kidney disease (CKD). The study revealed that while tirzepatide improved cardiovascular outcomes and slightly boosted kidney function, the benefits in CKD patients may stem from mechanisms beyond glomerular filtration alone.

Luis Hernandez, M.D., FACC, fellowship-trained Cardiologist and Medical Director of the Advanced Heart Failure Program at Monument Health Heart and Vascular Institute, gives insight on how devices like defibrillators, pacemakers and pulmonary pressure sensors manage heart failure and help prevent hospital readmissions. He also outlines the importance of medication and patient monitoring in improving heart failure outcomes. Dr. Hernandez brings plenty of visual aides in this episode so be sure to check out the video version on YouTube! Hosted on Acast. See acast.com/privacy for more information.

Drs Carol H. Wysham and Christopher M. Kramer discuss heart failure and type 2 diabetes, and the role of incretin therapies in the management of HFpEF. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002048. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources The Incidence of Congestive Heart Failure in Type 2 Diabetes: An Update https://pubmed.ncbi.nlm.nih.gov/15277411/ Hypertension in Diabetes: An Update of Basic Mechanisms and Clinical Disease https://pubmed.ncbi.nlm.nih.gov/34601960/ Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update https://pubmed.ncbi.nlm.nih.gov/31167558/ Insulin Resistance and Hyperinsulinaemia in Diabetic Cardiomyopathy https://pubmed.ncbi.nlm.nih.gov/26678809/ Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024 https://pubmed.ncbi.nlm.nih.gov/38078592/ The Paradox of Low BNP Levels in Obesity https://pubmed.ncbi.nlm.nih.gov/21523383 Tirzepatide for Heart Failure With Preserved Ejection Fraction and Obesity https://pubmed.ncbi.nlm.nih.gov/39555826/ Cardiovascular Effects of Incretin-Based Therapies: Integrating Mechanisms With Cardiovascular Outcome Trials https://pubmed.ncbi.nlm.nih.gov/35050311/ Beyond Weight Loss: the Emerging Role of Incretin-Based Treatments in Cardiometabolic HFpEF https://pubmed.ncbi.nlm.nih.gov/38294187/ Heart Failure With Preserved Ejection Fraction: Mechanisms and Treatment Strategies https://pubmed.ncbi.nlm.nih.gov/34379445/ Obesity and Heart Failure With Preserved Ejection Fraction: New Insights and Pathophysiological Targets https://pubmed.ncbi.nlm.nih.gov/35880317/ Epidemiology of Heart Failure in Diabetes: A Disease in Disguise https://pubmed.ncbi.nlm.nih.gov/38334818/ Semaglutide in Patients With Heart Failure With Preserved Ejection Fraction and Obesity https://pubmed.ncbi.nlm.nih.gov/37622681/ Mechanisms of Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure With Preserved Ejection Fraction https://pubmed.ncbi.nlm.nih.gov/37674356/ Finerenone in Heart Failure With Mildly Reduced or Preserved Ejection Fraction https://pubmed.ncbi.nlm.nih.gov/39225278/ Effects of Tirzepatide on Circulatory Overload and End-Organ Damage in Heart Failure With Preserved Ejection Fraction and Obesity: A Secondary Analysis of the SUMMIT Trial https://pubmed.ncbi.nlm.nih.gov/39551891/ Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, a Preserved Ejection Fraction, and Obesity https://pubmed.ncbi.nlm.nih.gov/39556714/ Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy https://pubmed.ncbi.nlm.nih.gov/39566869/6 Spironolactone for Heart Failure With Preserved Ejection Fraction https://pubmed.ncbi.nlm.nih.gov/24716680/

How One Leader Came Out of Retirement to Transform Home Healthcare Jasper Freeman, Director of National Accounts at SC Pharmaceuticals, didn't just return to medical sales—he came back with a mission to change it. In this episode, Jasper shares how he helped launch Ferosix, a revolutionary heart failure treatment designed to keep patients out of the hospital and improve care at home. But that's just the beginning. We dive into: The untold story of Pharmacy Benefit Managers (PBMs) and their massive influence over drug pricing and access Why the insurance-sales-patient triangle is the key battleground in healthcare innovation What the U.S. can learn from other countries about lowering costs and improving care Bold reform ideas—from slashing med school tuition to rethinking drug distribution This is a rare, behind-the-scenes look at the business of healthcare, guided by someone who's lived it at the highest levels. If you're in medical sales—or trying to break in—this episode is a masterclass on what's next and how to lead the change. Connect with Jasper: LinkedIn Connect with Me: LinkedIn Love the show? Subscribe, rate, review, and share! Here's How » Want to connect with past guests and access exclusive Q&As? Join our EYS Skool Community today!

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Aerobic Exercise Training, Biological Age, and Mortality in Chronic Heart Failure With Reduced Ejection Fraction.

Argentinians in the capital, Buenos Aires, paid tribute to Pope Francis during a mass held at the San Jose de Flores Basilica. The US Vice President JD Vance has met with India's prime minister Narendra Modi to discuss a trade deal. And the United Nations says, the cyberscam industry is expanding globally including to South America and Africa. We hear from International Justice Mission which has been campaigning to help the people forced to working at these scam centres.

In this episode, Dr. Valentin Fuster dives into the complex and high-stakes world of cardiogenic shock, spotlighting new clinical trials, expert consensus guidance, and cutting-edge insights from machine learning. From evaluating the impact of intra-aortic balloon pumps to rethinking mechanical support strategies, the episode delivers a powerful update on one of cardiology's most urgent challenges.

Focus Issue on Heart Failure and Cardiomyopathies

Send us a textWelcome back Rounds Table Listeners! We are back today with a solo episode with Dr. John Fralick. This week, he discusses a recently published trial examining liberal fluid intake vs. fluid restriction in chronic heart failure. Here we go!Liberal fluid intake versus fluid restriction in chronic heart failure: a randomized clinical trial (0:00 – 4:20).And for the Good Stuff:starpowerdrummer on YouTube (4:21 – 5:20).Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

In this episode of Nurse Converse, Shenell Thompkins is joined by Tiffany Cannon, who shares her powerful story of living with a Left Ventricular Assist Device (LVAD). At just 28, Tiffany experienced heart failure during pregnancy, leading to an emergency C-section and the life-changing decision to receive an LVAD. She opens up about the emotional toll, her return to nursing, and how her dual perspective as both a patient and nurse fuels her passion for advocacy, empathy, and patient empowerment. Tiffany's journey is one of resilience and hope, proving that heart disease is not the end—but a new beginning. >>One Nurse's Journey with LVAD (Left Ventricular Assistive Device)Jump Ahead to Listen: [02:17] Tiffany's journey to heart failure.[05:53] Heart failure diagnosis after childbirth.[09:23] Divine intervention in medical decisions.[13:25] Gratitude through life changes.[21:00] Bridging patient-nurse connection.[22:49] Advocacy and patient awareness.[26:18] Heart disease is not a death sentence.[29:09] Supporting nurses in their careers.Connect with Shenell on social media:Instagram: allonenurse_shenell  TikTok: all_one_nurseFor more information, full transcript and videos visit Nurse.org/podcastJoin our newsletter at nurse.org/joinInstagram: @nurse_orgTikTok: @nurse.orgFacebook: @nurse.orgYouTube: Nurse.org

Hosts Mitsuaki Sawano, MD, and Nobuhiro Ikemura, MD, welcome Yuichiro Mori, MD, MPH, a physician-scientist at Kyoto University, to discuss his ACC.25 poster presentation on biomarker-based pre-heart failure screening using NT-proBNP, conducted in a rural Japanese city in Hokkaido. Drawing from a screening cohort of 1,585 individuals aged 40–74 in Furano, the study integrated NT-proBNP testing into Japan's routine general health checkups. Dr. Mori shares key takeaways from the study and emphasizes how even single-site efforts, when well-structured and strategically communicated, can gain recognition at major global meetings like ACC.

In this powerful episode of the Everyday Miracles Podcast, host Julie welcomes special guest Camille to share her incredible story. Camille experienced severe heart failure in 2012, resulting in three comas. During this time, she had profound spiritual experiences, visiting both hell and heaven. Camille recounts her encounters with demonic realms and her ultimate rescue by God the Father, who reassured her of His protection and love. She describes the astounding process of spiritual and physical healing that followed her experience. With emphasis on faith, repentance, and the transformational power of God's love, Camille's testimony offers hope and inspiration. Join us for this amazing journey of faith and divine intervention.   00:00 A Journey Through Heaven and Hell  01:17 Introduction to Camille's Story  02:18 Camille's Background and Diagnosis  03:38 The Struggle with Heart Failure  07:33 Experiencing Hell  19:22 A Glimpse of Heaven  20:58 The Father's Voice and Healing  25:59 Life After the Experience  32:41 Heavenly Announcements and Angelic Parade Rest  33:10 The Voice of Many Waters  34:01 A Crystal Heart Shattered  34:58 Walking with the Maker of Everything  35:44 The Accordion of Universes  36:35 The Seven Universes Revelation  37:02 The Unforgivable Sin of Angels  37:24 Satan's Deception and Human Ignorance  38:50 The Purpose of Life: To Love  39:17 Returning to Earth: The Black Soot of Sin  40:58 Miraculous Healings and Divine Tips  47:09 Sharing the Testimony and Ministry Work  52:54 The Power of Repentance and Living for Christ   54:02 Closing Prayer and Final Thoughts    Isaiah 41:13:   "For I am the Lord your God, who takes hold of your right hand and says to you, 'Fear not, I will help you.'" To contact or follow Camille: https://www.facebook.com/camille.rose.ministries

Returning for a second study this month, the JHLT Digital Media Editors invite first author Charlotte Van Edom to discuss the paper, “Apixaban plasma levels in patients with HeartMate 3 support.” As a cardiologist in training and a PhD candidate at the University Hospitals Leuven in Belgium, Van Edom's work focuses on hemocompatibility and mechanical circulatory support, covering both short-term and long-term support. The episode explores: The evolution of the use and understanding of direct oral anticoagulants (DOACs) during LVAD support, including the increased focus on Factor Xa inhibitors Encouraging findings from the study and what clinical practices might need to change if introducing apixaban Additional studies exploring DOACs in LVAD patients For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt. Treat or research pulmonary vascular diseases? Check out the first April episode for a study on sotatercept in PAH patients. Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

In this episode, Dr. Kristen Nordenholz breaks down some of the causes and differential for right heart failure in EM. This ties in with the prior podcast from CoACEP with Dr. Tems talking about the indications for ECMO.

Editor's Summary by Linda Brubaker, MD, MS, and Chris Muth, MD, Deputy Editors of JAMA, the Journal of the American Medical Association, for articles published from March 29-April 4, 2025.

Join here for an insightful discussion with Federico Pappalardo, MD and Sanket Dhruva, MD, FACC on the groundbreaking ALT-SHOCK 2 RCT, the largest randomized trial on intra-aortic balloon pump therapy in heart failure cardiogenic shock. Learn about the trial's key findings, implications for clinical practice, and the future of mechanical circulatory support in this critically ill patient population.

A 70 year old man with a 35 year history of hypertension, dyslipidemia, and a 20 year history of type 2 diabetes presents. He was recently diagnosed with systolic heart failure, presenting with dyspnea on exertion and orthopnea. Prior clinical assessment revealed the murmur of mitral regurgitation. Which of the following would the NP anticipate finding on today's physical exam?  A. A mid to late systolic murmur that follows a mid systolic click. B. In early to mid systolic murmur harsh in quality, that radiates to the neck. C. A holosystolic murmur that radiates to the axilla.D. A localized mid to late diastolic murmur.---YouTube: https://www.youtube.com/watch?v=jN29-on3tn8&list=PLf0PFEPBXfq592b5zCthlxSNIEM-H-EtD&index=113Visit fhea.com to learn more!

The Trump administration announced plans to roll back multiple environmental regulations, cut EPA spending and push back environmental justice programs. We cover how recent federal actions impact environmental policy as well as the role our guest Christine Todd Whitman played as the former Administrator of the Environmental Protection Agency during the Bush administration. Also, plastics can contain thousands of chemicals like phthalates and PFAS which are harmful to human and animal health. A new study published in the journal Ecotoxicology and Environmental Safety, found that higher exposure to disposable takeout containers, was linked to a higher risk of congestive heart failure in both humans and animals. We discuss this study, and others related to plastics and health. And From abolitionist Harriet Tubman to novelist Louisa May Alcott, some of the country's most important women trailblazers shared a connection with the natural world in their girlhood. Tiya Miles shares their stories in her book Wild Girls: How the Outdoors Shaped the Women Who Challenged a Nation. Learn more about your ad choices. Visit megaphone.fm/adchoices

Story at-a-glance Heart failure affects 6.7 million Americans over the age of 20, and this number is expected to reach 8.5 million by 2030. Globally, it impacts over 37 million people as a life-threatening condition People who are hospitalized for severe infections like pneumonia or sepsis are more than twice as likely to develop heart failure Infections trigger an aggressive immune response that have a chance to become dysregulated, causing persistent inflammation and damage to the heart muscle's ability to pump efficiently The risk of heart failure persists long-term, with most cases appearing about seven years after the initial infection-related hospitalization Vitamin D produces antimicrobial peptides that protect against bacteria, fungi and viruses that cause severe infections, so make sure to optimize your levels through safe sun exposure